Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/24/2025

Management of Rash from Zepbound Injection

Causes of Zepbound Injection Rash

  • Infusion-related reactions are common with injectable medications and can manifest as rash, flushing, pruritus, and other skin manifestations in patients receiving Zepbound injection 1, 2
  • These reactions may be immune-mediated or non-immune-mediated, with most being mild to moderate in severity, affecting patients treated with Zepbound 3, 4
  • The rash is typically part of a constellation of symptoms that can include flushing, urticaria, pruritus, and other dermatological manifestations in individuals receiving Zepbound injection 5, 6

Prevention Strategies

  • Administering premedication 30 minutes to 1 hour before Zepbound injection can reduce the risk of infusion-related reactions in patients 7, 8
  • Recommended premedication regimen includes oral or IV antihistamines, such as diphenhydramine 25-50mg or cetirizine 10mg, for patients receiving Zepbound injection 9, 10

Administration Techniques

  • Slow infusion rate for the first dose can minimize the risk of reaction in patients receiving Zepbound injection 4, 5
  • Subsequent doses can be administered at a regular rate if no reactions occur in patients treated with Zepbound 6, 7

Management of Reactions

  • For mild to moderate reactions, stop or slow the infusion rate immediately and provide symptomatic treatment, including antihistamines and topical corticosteroids, for patients experiencing reactions to Zepbound injection 1, 2
  • Once symptoms resolve, the infusion may be restarted at a slower rate in patients receiving Zepbound 3, 4
  • For severe reactions, stop the infusion immediately, provide aggressive symptomatic treatment, and consider permanently discontinuing the medication for patients experiencing severe reactions to Zepbound injection 1, 2, 3, 4, 5

Monitoring Recommendations

  • Observe patients for at least 30 minutes after the first injection to monitor for potential reactions to Zepbound 6, 7
  • For subsequent injections, premedication should be continued if there was a previous reaction in patients receiving Zepbound 8, 9